WO2002090025A1 - Procede pour preparer une micropoudre contenant de l'argent nanometrique anti-agglomeration, micropoudre produite par ce procede et son application - Google Patents

Procede pour preparer une micropoudre contenant de l'argent nanometrique anti-agglomeration, micropoudre produite par ce procede et son application Download PDF

Info

Publication number
WO2002090025A1
WO2002090025A1 PCT/CN2001/001584 CN0101584W WO02090025A1 WO 2002090025 A1 WO2002090025 A1 WO 2002090025A1 CN 0101584 W CN0101584 W CN 0101584W WO 02090025 A1 WO02090025 A1 WO 02090025A1
Authority
WO
WIPO (PCT)
Prior art keywords
silver
nano
aggregation
antibacterial
fine powder
Prior art date
Application number
PCT/CN2001/001584
Other languages
English (en)
Chinese (zh)
Inventor
Hongjun Zhu
Li Zhu
Original Assignee
Shenzhen Tsinghua Yuanxing Nano-Material Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Tsinghua Yuanxing Nano-Material Co., Ltd. filed Critical Shenzhen Tsinghua Yuanxing Nano-Material Co., Ltd.
Publication of WO2002090025A1 publication Critical patent/WO2002090025A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A61L2/238—Metals or alloys, e.g. oligodynamic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F9/00—Making metallic powder or suspensions thereof
    • B22F9/16—Making metallic powder or suspensions thereof using chemical processes
    • B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
    • B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites

Definitions

  • the invention relates to a method for preparing nano-silver, a composite material prepared by the method and use of the composite material. More specifically, the present invention relates to a method for preparing anti-aggregation nano-silver, nano-silver-containing fine powder prepared by the method, and uses thereof. Background technique
  • Nanometer is a unit of length. One nanometer is equal to one billionth of a meter. Nanomaterials usually mean that the particle size of the material is between 1-100 nanometers, and it has special physical and chemical properties that are different from conventional sizes. It is one of the three major technologies for economic development in the 21st century, and it is also the new technology most likely to produce breakthrough achievements.
  • Peng Zifei and Zhang Lide's Chinese patent application discloses a method for preparing nanometer-scale silver with controllable size.
  • a certain concentration of silver nitrate solution is activated, concentrated ammonia water is added, and then a hydrogen peroxide solution is added.
  • the resulting precipitate is filtered, washed, and dried to obtain a white, highly dispersible nanometer silver powder. It can control the particle size of the silver powder according to the concentration of silver nitrate and the activation time.
  • a Chinese patent application by Zhou Quanfa discloses a method for preparing nano-scale silver powder.
  • the method is to dissolve silver nitrate by adding water, and then add ammonia water to prepare a silver ammonia solution, and then add a reducing agent and a protecting agent to prepare a reducing agent solution.
  • the silver in the silver ammonia solution is reduced to nano-scale silver powder.
  • After filtering out the silver powder It was immersed in oleic acid as a passivating agent, filtered to remove oleic acid, and dried under vacuum to obtain nano-grade silver powder with good stability and dispersibility.
  • these documents only refer to pure nano-silver powder, and there is no mention or suggestion of a method for preventing the aggregation of nano-silver and a composite material produced by the method.
  • Chinese patent application 99111155.9 by Jiang Jianhua et al. Discloses a nano-silver long-acting broad-spectrum antibacterial functional fabric and a manufacturing method thereof.
  • ultrafine silver is attached between or on the fibers of the fabric, the surface of the ultrafine silver is silver oxide, the core is metallic silver, and the particle diameter is 1-100 nanometers.
  • the invention does not mention the problem of preventing accumulation.
  • Chinese patent 94118576.1 relates to a long-acting broad-spectrum antibacterial particle, which uses a wicker stem as a carrier, and its surface is With nano-scale element silver.
  • the invention still does not mention the problem of anti-aggregation.
  • a bactericidal cloth which treats yarns with a resin solution containing a compound of copper and silver (average particle diameter of 6 microns) alone or in a mixture to The solution is evenly coated on the surface of the yarn and then woven into a sterilizing cloth.
  • the product can be used as the lining of rubber boots, canvas shoes and socks.
  • An object of the present invention is to provide a method for preventing aggregation of extremely active silver ultrafine particles during the formation of nano-silver, that is, a method for preparing fine powder containing anti-aggregation nano-silver.
  • Another object of the present invention is to provide a micropowder containing anti-aggregation nano-silver prepared by the method of the present invention.
  • Another object of the present invention is to provide a method for treating or preventing inflammatory diseases by using the micropowder containing anti-aggregation nano-silver according to the present invention, that is, the application of the micro-powder containing anti-aggregation nano-silver according to the present invention in the preparation of antibacterial and anti-inflammatory drugs.
  • Still another object of the present invention is to use the antibacterial and anti-inflammatory properties of the anti-aggregated nano-silver-containing fine powder of the present invention to prepare antibacterial and anti-inflammatory drugs, medical equipment, medical materials, cosmetics, health products and their functional applications in water purification equipment.
  • a method for preparing a micropowder containing anti-aggregation nano-silver includes the following steps:
  • aqueous solution A based on the total volume of aqueous solution A, which contains silver nitrate 0.01-1M, ammonia water 0.05-0.5M, and alkali metal hydroxide 0.01-0.3M;
  • step 1 10 parts by volume of solution A and 1 part by volume of solution B are mixed, and the mixture is left to stand for 10-40 minutes, and the solid porous fibrous material prepared in step 1 is impregnated with the mixed solution, and pressurized to make it uniform; Then put it into the reaction kettle and add dispersant to make it react, and heat treatment at the same time;
  • a micropowder containing anti-aggregation nano-silver prepared by the method of the present invention.
  • the nano-silver is firmly attached between the fibrous elements of the porous fibrous material and on the fibers.
  • the particle size of the nano-silver is 2-80 nm, preferably 5-40 nm, including silver oxide and elemental silver, the surface layer is 2-8 nm thick silver oxide, and the core is elemental silver.
  • the particle size of the fine powder is 0.5-10000 microns.
  • the silver content of the nano-silver particles attached between the fibrous elements of the porous fiber material and on the fiber is 0.1-200 mg / g porous fiber material.
  • a method for treating or preventing an inflammatory disease comprises administering to a patient a therapeutically effective amount of the microparticles containing anti-aggregation nanosilver according to the present invention.
  • various uses of the anti-aggregation nanosilver-containing fine powder of the present invention are provided.
  • antibacterial and anti-inflammatory drugs including nano-silver anti-bacterial anti-inflammatory gel for treating male prostatitis; nano-silver anti-bacterial and anti-inflammatory film for treating gynecological inflammation; oral ulcer film agent for oral ulcers; nano-silver wound patch, gauze, dressing, adhesive tape Band-aid or bandages for wound dressings; antibacterial aerosols and sprays for the oral cavity, ears, nose and throat; anti-inflammatory antibacterial membranes, antibacterial plugs, effervescent tablets and topical health care for gynecological inflammation Pads; skin care lotions, creams, creams, milks or masks; used in daily chemical products such as detergents and toothpastes with antibacterial effects.
  • the micro-powder containing the anti-aggregation nano-silver of the present invention can also be made into particles of 1-10 mm for purification of water systems
  • FIG. 1 is a scanning electron microscope photograph of anti-aggregation nano-silver prepared according to the anti-aggregation technology of the present invention. Tablets. ⁇
  • Figures 2-4 are SEM photographs of nanosilver prepared in the prior art without anti-aggregation technology. Summary of the Invention
  • a method for preparing a micro-powder containing a broad-spectrum antibacterial nano-silver includes the following steps:
  • aqueous solution A based on the total volume of aqueous solution A, which contains silver nitrate 0.01-1M, ammonia water 0.05-0.5M, and alkali metal hydroxide 0.01-0.3M;
  • the key is to prevent the aggregation of silver nanoparticles with nanometer-sized particle diameters that have a strong surface activity, thereby preventing the generation of silver particles with larger particle diameters.
  • a dispersant is added during the preparation.
  • the dispersant used is a conventional anti-aggregation agent known in the art, and specific varieties can be found in the manual, for example, isopropyl alcohol, sodium dodecylbenzenesulfonate, sodium succinatesulfonate , 0-10, and trialkyl phosphates (such as tributyl phosphate, trioctyl phosphate, triisoamyl phosphate, triisooctyl thiophosphate), etc.
  • the dispersant may be added continuously or intermittently.
  • nano-ultrafine particles with a particle size of 1-100 nanometers have a larger specific surface and are inversely proportional to the particle size. Due to the decrease in particle size, the number of atoms in the surface layer increased rapidly, resulting in insufficient original coordination, increased exposure of unsaturated bonds, and increased surface energy of the atoms, resulting in the extremely high chemical activity of these nanoscale ultrafine particles. The moment the ultrafine particles are generated, it is inevitable that they will collide with each other. The collision of two, even multiple ultrafine particles will occur, resulting in a large particle size, which can be several times, tens, hundreds of times larger than the original particle size, and even become macro due to agglomeration.
  • the present invention uses appropriate chemical and physical means to prevent the agglomeration of newly generated ultrafine particles.
  • This anti-agglomeration technology is crucial to the success of the method of making nano-ultrafine particles based on chemical methods and supplemented by physical methods.
  • FIG. 4 is a scanning electron micrograph of the anti-aggregation-preventing nano-silver micropowder according to the present invention using the anti-aggregation technology, clearly showing that most of the ultra-fine particles on the anti-aggregation-containing nano-silver micro powder of the present invention have a particle size of 5 -40 nm, and the distribution is neat and uniform. There is a strip-shaped bulge in the middle of the photo, but it is clear that it is not a spherical superfine particle accumulation.
  • the spherical ultrafine particles were measured by a photoelectron spectrometer.
  • the surface layer of the spherical ultrafine particles was 2-8 nanometers thick silver oxide, and the core was elemental silver.
  • the silver content of the nano-silver on the fine powder containing the anti-aggregation nano-silver is 0.1-200 mg I g.
  • the porous fibrous material used is selected from natural multi-porous plant fibers, such as fiber pulp of wicker, cotton, wool, hemp, silk, bamboo, and wood, and stems of reed flowers and loofah plants Porous carriers, such as activated carbon; chemical fibers; non-woven fabrics or foamed plastics.
  • the preferred porous fibrous material is a natural porous plant fiber, and more preferred is rush.
  • the alkali metal hydroxide used is NaOH [or KOH, preferably NaOH.
  • the weak reducing agent used is selected from glucose, ascorbic acid, hydrazine hydrate or sodium borohydride. Glucose or ascorbic acid is preferred.
  • pressurization can be performed by conventional methods in the art, such as mixing, stirring, pairing, and spraying.
  • the temperature of the heat treatment used may vary depending on the ignition point of the porous fiber used, as long as it does not exceed the ignition point of the porous fiber. For example, when the porous fiber is rush grass, the heat treatment temperature is 100-150 ° C.
  • the heat treatment time is specifically determined according to the amount of the carrier material. The larger the amount of carrier material, the longer the heat treatment time, If the amount is small, the heat treatment time is short. For example, for a wicker carrier, heat treatment is required until the product is brownish yellow. Afterwards, it can be washed, dried, and pulverized to obtain the refined powder product. If large particles are required, such as 1-10 mm particles, then no further pulverization is required.
  • a micro-powder containing anti-aggregation nano-silver prepared by the method of the present invention, and the nano-silver particles are firmly attached between the fiber elements of the porous fibrous material and on the fiber.
  • the particle size is 2 to 80 nm, preferably 5 to 40 nm, including silver oxide and elemental silver, the surface layer is 2 to 8 nm thick silver oxide, and the core is elemental silver.
  • the fine powder has a particle size of 0.5-10000 microns.
  • the silver content of the nano-silver particles attached between the fibrous elements and the fibers of the porous fiber material is 0.1-200 mg / g porous fiber material.
  • the fine powder containing the anti-aggregation nano-silver of the present invention has a particle size of 0.5-10000 microns, and the specific size varies according to different uses.
  • the size of the micro-powder is 0.5-100 micrometers, preferably 0.5-25 micrometers; if used for the purification of water systems, the micro-powder size is 100-10000 micrometers, preferably 2000-8000 micrometers.
  • the anti-aggregation nano-silver-containing fine powder of the present invention is a composite material in which nano-silver is attached to a carrier material.
  • the carrier material used is a porous fiber material, which may be a natural porous plant material, such as fiber pulp of wicker, cotton, wool, hemp, silk, bamboo and wood, and stems of reed flowers and loofah plants; porous Carriers, such as activated carbon; chemical fibers; non-woven fabrics or foamed plastics.
  • the preferred porous fibrous material is a natural porous plant material, such as fibers of rush, cotton, wool, linen, silk, bamboo and wood, and more preferably rush.
  • the prepared micro-powder containing anti-aggregation nano-silver of the present invention is added with appropriate medical additives or excipients to prepare powders, tablets, pastes, creams, films, Gels, patches, injections, liquids, sprays and biomedical chips.
  • the product of the invention can be used as a medical (external) material for treating burns and scalds, as well as for treating skin infections and superficial skin fungal infections in patients with trauma, as well as materials for preventing and treating incision infections after surgical incisions, and can also be used as hygiene in daily life. Supplies, with broad-spectrum antibacterial, long-lasting, killing drug-resistant pathogens, hydrophilicity-stronger sterilization ability in contact with water, non-toxicity (including non-accumulative toxicity), non-irritant, non-allergic , Excellent performance such as non-drug resistance. It can be used to treat skin infections and skin fungal infections as well as surgical incision infections in patients with trauma.
  • the products of the present invention can be used to treat refractory bedsore infections, mixed infections of burns and burns, refractory ulcers in late diabetes, prevention and treatment of bacterial, fungal and mixed infections vaginitis in women, prostatitis in men, etc.
  • sexual infections, washing and cleaning have created an industrialized example of the application of nanotechnology in the field of human anti-infection.
  • Micropowder containing anti-aggregation nano-silver and control Antibacterial drug MIC method sensitivity results
  • the AB fabric is a fabric disclosed by CN-87100231A.
  • MRSA Staphylococcus aureus resistant strains
  • MRSA Staphylococcus aureus resistant strains
  • Pseudomonas aeruginosa Pseudomonas maltophilia and nitrate-negative bacilli
  • After high pressure and washing for 20 and 50 times they have no significant effect on the bacteriostatic effect after washing for 20 and 50 times. After washing for 20 times, none of the upper bacteria can be inhibited. Therefore, it can be seen that the micronized powder containing the anti-aggregation nano-silver has a broader bacteriostatic range than the AB fabric and does not affect the bacteriostatic effect due to washing.
  • the antibacterial mechanism of the micro-powder containing anti-aggregation nano silver of the present invention is a classic antibacterial mechanism:
  • micropowder containing anti-aggregation nano-silver is the most classic antibacterial mechanism.
  • the -SH group in the enzyme that depends on the survival of the bacteria is replaced with -SAg, which causes the enzyme to lose its activity and causes the death of the bacteria.
  • the product is Enzymes 2SAg and H 2 0, there are no secondary pathogenic factors.
  • micropowder containing anti-aggregation nano-silver of the present invention has the following superior special functions.
  • the bacterial species shown in Tables 1 and 2 include Gram-positive bacteria, Gram-negative bacteria, fungi, spores, and anaerobic bacteria. Such a broad antibacterial spectrum is extremely rare among existing antibacterial drugs. There are 38 strains of bacteria removal duplicates in Tables 1 and 2, and most of them were isolated from the secretions of clinically resistant patients.
  • the medicaments with different dosage forms of the nano silver fine powder of the present invention are non-sensitive Inflammatory inflammation: certain types of arthritis, frostbite, fibrosis, allergic diseases such as Lyme arthritis, enlarged prostate, hay fever, psoriasis, eczema, Meniere's disease, skin cancer, chronic fatigue, Diseases such as low immunity are effective.
  • micro-powder containing anti-aggregation nano-silver and 8 antibacterial drugs on pathogenic bacteria-Table 1 shows the micro-powder containing anti-aggregation nano-silver according to the present invention. (28) and erythromycin (7), Ampicillin (4), cefuroxime (4), ceftazidime (15), oxacillin (2), gentamicin (6), ciprofloxacin (14) 8 antibacterial drugs are also tested in vitro . The number in parentheses after each drug name is the number of bacteria that the drug can inhibit.
  • micropowder containing the anti-aggregation nano-silver of the present invention may gradually become a bactericidal substance instead of antibiotics.
  • the micro-powder containing anti-aggregation nano-silver has no significant decrease in bacteriostatic effect after repeated rubbing.
  • the main mechanism is that Ag 2 0 on the micro-powder containing anti-aggregation nano-silver has a slow-release property. In the presence of water, even the humidity of the human body surface or the amount of water in the wet state during application is sufficient to release Ag +. When [Ag +] reaches 0.n-5ppm [l (T 6 ], it can reach Ag +. Dynamic equilibrium, and the minimum bacteriostatic concentration of Ag + is SX IO ⁇ M, as for the antibacterial mechanism containing the anti-aggregation nano-silver powder.
  • the antibacterial mechanism and the secondary pathogenic factors that do not cause secondary pathogenic factors during the antibacterial process are in the previous "antibacterial mechanism" section.
  • the following test was also performed, taking 0.5 g of anti-aggregation nano-silver particles, immersed in 500 ml of water every day, and changing the water once a day. After 45 days, the coarse powder containing anti-aggregation nano-silver fine powder had no bacteriostatic effect. Significantly reduced. Therefore, the external medicine made with the powder containing anti-aggregation nano-silver as the raw material medicine has stronger antibacterial force in water.
  • mice Mice, guinea pigs and big eared white rabbits were used as test subjects, and micro-powder containing anti-aggregation nano silver was used as experimental drugs.
  • Acute skin toxicity test, irritability test, allergy test and mice Acute toxicity test, maximum tolerance test, and accumulation toxicity test, especially for mice (9) given a single intragastric administration of micropowder containing anti-aggregation nano-silver for a maximum tolerance of 925 mg I kg, equivalent to human
  • the planned clinical dose was 4625 times. After continuous observation for 14 days, no symptoms of poisoning and death were found, and the growth was good.
  • micropowder containing the anti-aggregation nano-silver was non-toxic, non-irritating, non-allergenic, and non-resistant. Silver entering the human body can be excreted through urine and feces, so silver has no cumulative toxicity.
  • the functions of the anti-aggregation nano-silver-containing fine powder of the present invention include broad-spectrum antibacterial properties, long-lasting properties, bacteriostatic ability against drug-resistant pathogenic bacteria, and hydrophilicity-water-resistant sterilization ability is more Strong, non-toxic (including no accumulated toxicity), non-irritant, non-allergenic, non-resistance, etc. are far superior to the commonly used antibacterial drugs, and far superior to the macro-sized homogeneous silver micropowder.
  • the silver particles on the micropowder containing the anti-aggregation nano-silver were found to have particularly superior antibacterial properties.
  • another aspect of the present invention provides a method for treating or preventing inflammatory diseases by using the micropowder containing the anti-aggregation broad-spectrum antibacterial nano-silver according to the present invention.
  • the micropowder containing anti-aggregation nano silver of the present invention can be made into creams, lotions, tablets, capsules, pills, dispersible powders, granules, suppositories, syrups, lozenges, injections, suspensions or emulsions, patches In the form of a spray, spray, aerosol or biomedical chip.
  • the inflammation includes male prostatitis, gynecological bacterial, fungal, chlamydia, mycoplasma, viral alone or mixed vaginitis, cervical erosion and cervicitis, purulent infections, bacterial skin infections, skin fungal infections, post-surgical operations Incisional infections, refractory bedsore infections, burns and burns infections, post-diabetic lower limb refractory ulcers, contact dermatitis, diaper dermatitis, acne, hemorrhoids, oral bacteria, fungi, chlamydia, mycoplasma or virus infection, upper and lower respiratory tract bacteria, Fungal, chlamydia, mycoplasma, or virus infections and bacterial, fungal, chlamydia, mycoplasma, or virus infections in the digestive tract.
  • the drug can be administered via oral, sublingual, intravenous, subcutaneous, transdermal, intramuscular, intradermal, intrathecal, epidural, intraocular, throat, nasal, inhalation, rectal, vaginal administration Medicine, etc.
  • the active ingredient can be mixed with a pharmaceutically acceptable carrier such carriers as glucose, lactose, acacia, gelatin, mannitol, starch, magnesium trisilicate, talc, corn starch, keratin, potato starch, urea, glucose Glycan and so on.
  • a pharmaceutically acceptable carrier such carriers as glucose, lactose, acacia, gelatin, mannitol, starch, magnesium trisilicate, talc, corn starch, keratin, potato starch, urea, glucose Glycan and so on.
  • various excipients such as calcium carbonate, lactose, calcium phosphate, sodium phosphate and the like as well as various granulating agents and disintegrating agents such as corn starch, potato starch, alginic acid, etc., and a binder such as Tablets, capsules, dragees, aqueous suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups and lozenges of tragacanth, corn starch, gelatin, acacia, etc.
  • Lubricants such as triethylamine magnesium stearate, triethylamine stearate, talc and the like can also be added.
  • Oral-administered formulations may be prepared according to any method known in the art for preparing pharmaceutical formulations, and such formulations may contain one or more adjuvants selected from the following to provide palatable pharmaceutical formulations: sweeteners such as sucrose , Lactose, saccharin, etc., flavoring agents such as mint, holly oil, etc.
  • Formulations for oral administration may also contain suitable carriers, including emulsions, solutions, suspensions, sugar paddles, and the like, and optionally contain additives such as wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents, flavorings, and the like.
  • the tablets may be uncoated or they may be coated by known techniques to delay their disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • suitable carriers include sterile water, suspensions, or emulsions.
  • suitable carriers include propylene glycol, polyethylene glycol, gelatin, and injectable organic esters such as ethyl oleate and the like.
  • Such dosage forms may also contain adjuvants such as wetting agents, emulsifying agents and dispersing agents J.
  • Aqueous solutions can also be suitable for intravenous, intramuscular, intrathecal, subcutaneous, intraperitoneal, and intrapleural injection.
  • the sterile aqueous media used are readily prepared by standard techniques well known to those skilled in the art.
  • the anti-aggregation nano-silver-containing fine powder for implementing the present invention can also be administered in the form of a rectal or vaginal pharmaceutical suppository, effervescent tablet, film, or liquid.
  • These compositions can be prepared by combining the micropowder containing anti-aggregation nanosilver of the present invention and a suitable pharmaceutically acceptable carrier.
  • the preferred therapeutic dose varies depending on the clinical indication. Depending on the condition of the patient being treated, certain changes to the dose may have to be made, and in any case, by a doctor The physician determines the appropriate dose for the individual patient.
  • the effective amount of the nano-silver-containing fine powder of the present invention per unit dose depends on body weight, physiological condition, selected administration schedule, and the like.
  • the route of administration of the nanosilver-containing micropowder used to practice the present invention depends on the disease and the site in need of treatment.
  • the pharmaceutical preparation can be administered parenterally in any pharmaceutical dosage form or composition by skin application. It is used as a therapeutic agent alone or in combination with other pharmaceutical preparations. Single and multiple treatment dosage regimens are useful in treatment regimens.
  • terapéuticaally effective amount when used in the method of the invention using the nanosilver-containing micropowder of the invention, means a dose sufficient to provide a concentration high enough to provide a beneficial effect to the recipient.
  • the specific therapeutically effective dose level will depend on a number of factors, including the disease being treated, the severity of the disease, the route of administration used, the duration of treatment, the specific drug used in conjunction with or concurrent with the specific compound, the patient's Well-known factors in the medical sciences such as age, weight, gender, diet and general health.
  • a nano-silver antibacterial anti-inflammatory gel for treating male prostatitis prepared by using the anti-aggregation nano-silver micropowder according to the present invention is provided. It is prepared according to methods known in the art. It contains the anti-aggregation broad-spectrum antibacterial nano-silver fine powder of the present invention, and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier used may be a pharmaceutically acceptable carrier known in the art, including monomer carriers, surfactants, dispersants, and transdermal enhancers.
  • the monomer carrier used is a natural or synthetic polymer gel material, preferably polyethylene glycol (PEG).
  • the surfactant used may be an ionic or non-ionic surfactant, preferably sodium lauryl sulfate.
  • the dispersant used may be a macromolecular polymer, a surfactant, and an organic acid dispersant, and sodium lauryl sulfate is preferred.
  • the transdermal enhancers used are natural or synthetic polymers and synthetic elastomers, preferably glycerol.
  • the nano-silver antibacterial anti-inflammatory gel for treating male prostatitis of the present invention can be used for rectal administration of male multiple prostatitis and elderly male organic prostate disease, and can also treat human hemorrhoids.
  • a nano silver antibacterial anti-inflammatory film for treating gynecological inflammation prepared by using the anti-aggregation broad-spectrum antibacterial nano silver fine powder of the present invention is provided. It can also be made into effervescent tablets, suppositories or topical sanitary tablets. It is prepared according to methods known in the art.
  • the antibacterial anti-inflammatory film it contains the anti-aggregation nano-silver-containing fine powder of the present invention and a pharmaceutically acceptable carrier.
  • the film thickness is 10-100 micrometers, and the nano-silver content is 1-50 yg / cm 2 .
  • the pharmaceutically acceptable carrier used may be a pharmaceutically acceptable carrier well known in the art, including a monomer carrier, a surfactant, a disintegrant, and a transdermal enhancer.
  • the monomer carrier used is a natural or synthetic polymer gel material, Polyvinyl alcohol (PVA) is preferred.
  • the surfactant used may be an ionic surfactant or a non-ionic surfactant, preferably sodium lauryl sulfate.
  • the disintegrants used may be starch and starch derivatives, cellulose surfactants, effervescent mixtures and gums, preferably sodium starch glycolate.
  • the transdermal enhancers used are natural or synthetic polymers and synthetic elastomers, preferably nitrocellulose.
  • the nano-silver antibacterial anti-inflammatory film for treating gynecological inflammation can be used for preventing and treating gynecological bacterial vaginitis, fungal vaginitis and mixed infection vaginitis, and can also be used for preventing and treating gonorrhea and cervicitis.
  • the fine powder of the present invention can be sprayed on a conventional external sanitary pad.
  • the micropowder containing anti-aggregation nano-silver of the present invention can be mixed with a pharmaceutically acceptable carrier.
  • a wound dressing such as a wound patch, gauze, dressing, adhesive tape, band-aid, or bandage, which is prepared by using the anti-aggregation broad-spectrum antibacterial nano-silver fine powder according to the present invention.
  • the carrier material is sprayed or permeated with the fine powder containing the anti-aggregation nano-silver of the present invention.
  • the wound patch it is composed of the anti-aggregation broad-spectrum antibacterial nano-silver fine powder, medical glue, fiber material, and medical sticker material of the present invention.
  • the fiber material is pasted on the medical adhesive material, and the medical glue and the anti-aggregation broad-spectrum antibacterial nano silver fine powder of the present invention are sprayed on the upper part of the fiber material.
  • the fiber material used may be a fabric made of natural or synthetic fibers, such as cotton, linen, wool, silk, wood fibers, nylon, polyester or vinylon.
  • the wounds made may be penetrating, island-shaped or quadrangular.
  • the present invention also provides skin care emulsions, creams, ointments, milks and facial masks containing the micropowders of the present invention, which is a mixture of the present inventions and micropowders with oil-in-water emulsions, creams, ointments, milks and mask powders. Even, it has antibacterial, anti-inflammatory and skin-care effects. For example, after preparing the emulsion or cream with the required ingredients according to a conventional oil-in-water process, adding an appropriate amount of microparticles containing anti-aggregation nano-silver with a particle diameter of 0.5-10 microns, and pressurizing and homogenizing, it can be prepared. The product of the invention is obtained.
  • the micropowder containing anti-aggregation nano-silver of the present invention can be used in a sterilization device in a water purification device of a space station.
  • the general structure of a water sterilization device is as follows: a cylinder with a round cap with a threaded mouth; a soft elastic tube for water inlet or outlet each at the bottom of the cylinder cover; the cylinder is equipped with 3-4 layers of storage
  • the nylon mesh divides the baffle, which can bear the weight of the sterilized material after soaking in layers, which is conducive to the smooth flow of water.
  • the flow of the outlet pipe is controlled to adjust the amount of water. Take a sterilizer that can handle 20 to 30 liters of water per day for 10 people as an example.
  • the cylinder with the above structure is filled with 100 grams of anti-aggregation nano-silver with a particle size of 1 to 10 mm. Particles.
  • the cylinder is made according to the volume of 100 grams of particles after being soaked in water.
  • the cylinder weight is not more than 400 grams, and the net weight of the sterilizer is not more than 500 grams.
  • the sterilization period is not less than 1 year. The sterilization process does not consume any energy and medicines, and its size can be used in homes or medical units.
  • micro-powder containing anti-aggregation nano-silver of the present invention can also be used as a pure natural additive for foods and beverages with bacteriostatic and fresh-keeping effects; a cleaning solution or soaking solution for cleaning the genitals and wounds of men and women; and a bacteriostatic effect Daily chemical products such as detergents, mouthwashes and toothpaste; and functional components used in biochips.
  • M is the molar concentration
  • Dispensing pharmaceutical liquid according to the following amount (based on 10 kg carrier) A. Prepare 500 liters of solution A, of which AgN0 3 0.3M, N3 ⁇ 4 3 ⁇ 40 0.2M, NaOH 0.07M, and the balance is water;
  • Formulation A 4 kg of polyvinyl alcohol (PVA17-88 1.6 kg, PVA25-99 2.4 kg) are dissolved in 20 liters of water, 0.8 kg of sodium starch glycolate is added to dissolve, and the anti-aggregation broad-spectrum antibacterial nanosilver of the present invention is added. 100 grams of fine powder, stirred into a uniformly suspended aqueous solution.
  • the B solution was evenly coated on a horizontal glass plate, and after drying at 40 ° C, the C solution and the A solution were applied in that order, and heated in a 40 ° C water bath to dry sufficiently.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Composite Materials (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte à un procédé servant à préparer une micropoudre contenant de l'argent nanométrique anti-agglomération, à une micropoudre contenant de l'argent nanométrique anti-agglomération et aux utilisations de cette micropoudre. Le procédé faisant l'objet de cette invention peut servir à empêcher l'agglomération de granules d'argent nanométrique à forte action. Ce procédé comprend une étape consistant à ajouter un dispersant pendant la réaction et une étape de traitement thermique. La micropoudre contenant de l'argent nanométrique anti-agglomération produite par ce procédé peut servir d'antibiotique à large spectre et d'agent anti-inflammatoire, et elle peut être utilisée comme élément antiseptique en pharmacie, dans des équipements médicaux, dans du matériel médical, en cosmétique, dans des systèmes d'épuration d'eau, en particulier dans des équipements par exemple pour stériliser de l'eau dans des engins spatiaux, dans des aérosols, dans des additifs alimentaires et dans des boissons, dans des constituants fonctionnels de biopuces, de détergents et de pâtes dentifrice, notamment.
PCT/CN2001/001584 2001-04-20 2001-11-26 Procede pour preparer une micropoudre contenant de l'argent nanometrique anti-agglomeration, micropoudre produite par ce procede et son application WO2002090025A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CNB011107677A CN1179646C (zh) 2001-04-20 2001-04-20 防集聚广谱抗菌纳米银微粉及产业化制作工艺
CN01110767.7 2001-04-20
CN01223000U CN2479952Y (zh) 2001-04-20 2001-05-08 纳米银创伤贴
CN01223000.6 2001-05-08
CNB011295074A CN1169529C (zh) 2001-04-20 2001-06-22 纳米银前列腺炎抗菌消炎凝胶及其工业化生产工艺
CN01129505.8 2001-06-22
CN01129505A CN1328819A (zh) 2001-04-20 2001-06-22 纳米银妇科病抗菌消炎膜及其工业化生产工艺
CN01129507.4 2001-06-22

Publications (1)

Publication Number Publication Date
WO2002090025A1 true WO2002090025A1 (fr) 2002-11-14

Family

ID=27429906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/001584 WO2002090025A1 (fr) 2001-04-20 2001-11-26 Procede pour preparer une micropoudre contenant de l'argent nanometrique anti-agglomeration, micropoudre produite par ce procede et son application

Country Status (2)

Country Link
CN (5) CN1179646C (fr)
WO (1) WO2002090025A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10346387A1 (de) * 2003-10-07 2005-06-09 Henkel Kgaa Antimikrobielle Ausrüstung von Bad- und WC-Artikeln
CN100386369C (zh) * 2005-06-03 2008-05-07 陈汝霖 新型纳米银乳胶制品及其制作方法
WO2007144057A3 (fr) * 2006-06-16 2008-11-06 Merck Patent Gmbh Carbone antimicrobien
US7589052B2 (en) * 2004-07-15 2009-09-15 Imec Slurry composition and method for chemical mechanical polishing of copper integrated with tungsten based barrier metals
US8399027B2 (en) 2005-04-14 2013-03-19 3M Innovative Properties Company Silver coatings and methods of manufacture
CN103341642A (zh) * 2013-07-26 2013-10-09 莆田学院 一种纳米银粒子的纤维素绿色合成法
US8815307B2 (en) * 2008-12-31 2014-08-26 Colotex Industrial Co., Ltd. Process for producing porous polymer masterbatch and fiber thereof having anti-bacterial and odor eliminating functions
US9289450B2 (en) 2006-01-13 2016-03-22 3M Innovative Properties Company Silver-containing antimicrobial articles and methods of manufacture
WO2020163435A1 (fr) * 2019-02-05 2020-08-13 Griffith Foods International Inc. Agent anti-agglomérant ou agent fluidifiant pour un assaisonnement ou des produits pharmaceutiques ou nutraceutiques
CN111763365A (zh) * 2020-07-17 2020-10-13 安信纳米生物科技（珠海）有限公司 一种含有纳米银的抗菌保鲜材料及其制备方法
CN113664213A (zh) * 2021-08-04 2021-11-19 湖南伟方生命科技有限公司 一种纳米银抗菌液的制备方法及其应用
CN115137681A (zh) * 2022-06-23 2022-10-04 深圳市黄田荔枝品牌发展有限公司 一种荔枝面膜及其制备方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7137968B1 (en) 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
US6719987B2 (en) 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
US7427416B2 (en) 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
DE60107253T2 (de) 2000-07-27 2005-12-01 Nucryst Pharmaceuticals Corp., Fort Saskatchewan Verwendung von edelmetallen zur herstellung eines arzneitmittels zur behandlung von hyperproliferativen hautstörungen und krankheiten
US7255881B2 (en) 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
US20030185901A1 (en) 2000-07-27 2003-10-02 Burrell Robert E. Methods of treating conditions with a metal-containing material
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US6989157B2 (en) 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
ES2261659T3 (es) 2001-04-23 2006-11-16 Nucryst Pharmaceuticals Corp. Un medicamento o una preparacion que contiene un metal tal como plata, oro, platino o paladio como un agente antimicrobiano y su uso para el tratamiento de estados inflamatorios de la piel.
US7201925B2 (en) 2002-04-23 2007-04-10 Nueryst Pharmaceuticals Corp. Treatment of ungual and subungual diseases
AU2002315728A1 (en) * 2002-06-03 2003-12-19 Shenzhen Tsinghua Yuanxing Nano-Material Co., Ltd. Composite nanostuctured silver
WO2007017901A2 (fr) * 2005-06-08 2007-02-15 Khandelwal Sanjeev Preparation a dispersion de nanoparticules d'argent
CN100457084C (zh) * 2006-08-04 2009-02-04 武汉正午阳光医药生物科技有限公司 纳米银妇女外用抗菌凝胶的制备方法
CN100396290C (zh) * 2006-11-03 2008-06-25 段炬红 妇科外用抗菌泡沫剂
CN101049279B (zh) * 2007-04-30 2010-06-23 东莞市拓扑光电科技有限公司 一种纳米银抗菌洗发露及其制备方法
WO2009085651A1 (fr) 2007-12-20 2009-07-09 Nucryst Pharmaceuticals Corp. Particules de carbonate de métal et leurs méthodes d'obtention
CN102430761A (zh) * 2011-12-12 2012-05-02 池州学院 一种可用于灭钉螺的水溶性纳米银的制备方法
CN103688996B (zh) * 2013-11-28 2014-12-10 太原理工大学 一种用废旧棉纤维制备载银抗菌剂的方法
CN105640986A (zh) * 2014-11-28 2016-06-08 广东工业大学 一种可用于肺癌和前列腺癌防治的纳米银组合物
CN107598186B (zh) * 2017-08-30 2019-08-20 苏州工业园区格云环保新材料有限公司 一种纳米银及其熏蒸液的制备方法
CN109137490A (zh) * 2018-06-27 2019-01-04 苏州市天翱特种织绣有限公司 一种棉纤维的抗菌改性方法
CN114028318B (zh) * 2021-10-14 2023-11-21 湖南伟方生命科技有限公司 一种男性抗菌液及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07173022A (ja) * 1993-12-17 1995-07-11 Asahi Chem Ind Co Ltd 抗菌剤
CN1123665A (zh) * 1994-11-26 1996-06-05 蒋建华 长效广谱抗菌颗粒及其制品的制作方法
JPH1088206A (ja) * 1996-09-12 1998-04-07 Dowa Mining Co Ltd 銀粉および銀粉の製造方法
CN1241662A (zh) * 1999-07-27 2000-01-19 蒋建华 纳米银长效广谱抗菌功能性织物及其制造方法
CN1266761A (zh) * 2000-03-23 2000-09-20 南京大学 纳米级银粉的制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07173022A (ja) * 1993-12-17 1995-07-11 Asahi Chem Ind Co Ltd 抗菌剤
CN1123665A (zh) * 1994-11-26 1996-06-05 蒋建华 长效广谱抗菌颗粒及其制品的制作方法
JPH1088206A (ja) * 1996-09-12 1998-04-07 Dowa Mining Co Ltd 銀粉および銀粉の製造方法
CN1241662A (zh) * 1999-07-27 2000-01-19 蒋建华 纳米银长效广谱抗菌功能性织物及其制造方法
CN1266761A (zh) * 2000-03-23 2000-09-20 南京大学 纳米级银粉的制备方法

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10346387A1 (de) * 2003-10-07 2005-06-09 Henkel Kgaa Antimikrobielle Ausrüstung von Bad- und WC-Artikeln
US7589052B2 (en) * 2004-07-15 2009-09-15 Imec Slurry composition and method for chemical mechanical polishing of copper integrated with tungsten based barrier metals
US8080505B2 (en) 2004-07-15 2011-12-20 Imec Slurry composition and method for chemical mechanical polishing of copper integrated with tungsten based barrier metals
US8399027B2 (en) 2005-04-14 2013-03-19 3M Innovative Properties Company Silver coatings and methods of manufacture
CN100386369C (zh) * 2005-06-03 2008-05-07 陈汝霖 新型纳米银乳胶制品及其制作方法
US9289450B2 (en) 2006-01-13 2016-03-22 3M Innovative Properties Company Silver-containing antimicrobial articles and methods of manufacture
WO2007144057A3 (fr) * 2006-06-16 2008-11-06 Merck Patent Gmbh Carbone antimicrobien
US8815307B2 (en) * 2008-12-31 2014-08-26 Colotex Industrial Co., Ltd. Process for producing porous polymer masterbatch and fiber thereof having anti-bacterial and odor eliminating functions
CN103341642A (zh) * 2013-07-26 2013-10-09 莆田学院 一种纳米银粒子的纤维素绿色合成法
WO2020163435A1 (fr) * 2019-02-05 2020-08-13 Griffith Foods International Inc. Agent anti-agglomérant ou agent fluidifiant pour un assaisonnement ou des produits pharmaceutiques ou nutraceutiques
US11602565B2 (en) 2019-02-05 2023-03-14 Griffith Foods International, Inc. Bamboo extract anti-caking and flow agents for dry powdered foods, food ingredients, pharmaceuticals and nutraceuticals
CN111763365A (zh) * 2020-07-17 2020-10-13 安信纳米生物科技（珠海）有限公司 一种含有纳米银的抗菌保鲜材料及其制备方法
CN113664213A (zh) * 2021-08-04 2021-11-19 湖南伟方生命科技有限公司 一种纳米银抗菌液的制备方法及其应用
CN113664213B (zh) * 2021-08-04 2023-11-21 湖南伟方生命科技有限公司 一种纳米银抗菌液的制备方法及其应用
CN115137681A (zh) * 2022-06-23 2022-10-04 深圳市黄田荔枝品牌发展有限公司 一种荔枝面膜及其制备方法

Also Published As

Publication number Publication date
CN1179646C (zh) 2004-12-15
CN1322474A (zh) 2001-11-21
CN2479952Y (zh) 2002-03-06
CN1505551A (zh) 2004-06-16
CN1169529C (zh) 2004-10-06
CN1328819A (zh) 2002-01-02
CN1224479C (zh) 2005-10-26
CN1328827A (zh) 2002-01-02

Similar Documents

Publication Publication Date Title
WO2002090025A1 (fr) Procede pour preparer une micropoudre contenant de l'argent nanometrique anti-agglomeration, micropoudre produite par ce procede et son application
CA2587029C (fr) Materiaux contenant du cuivre pour le traitement des blessures, des brulures et d'autres etats cutanes
EP2881122B1 (fr) Di-quaternäre ammoniumsalze aus organosilikon als antibakterielle mittel
CN105188719A (zh) 亚稳态的银纳米颗粒复合物
US20160287741A1 (en) Metastable silver nanoparticle composites with color indicating properties
WO2017185714A1 (fr) Matériau non tissé antibactérien en nanofibres et son procédé de préparation
TW201336483A (zh) 一種女性衛生用品
CN108273118A (zh) 含氧化石墨烯-铜银纳米复合物的中药抗菌卫生巾
WO2006128336A1 (fr) Nouveaux articles en latex renfermant des nanoparticules d'argent et leur preparation
CN1291667A (zh) 纳米银抗菌布及其工业化生产工艺
Sankar et al. Biological evaluation of nanosilver incorporated cellulose pulp for hygiene products
CN1322874A (zh) 防集聚广谱抗菌纳米银纱线及产业化制作工艺
CN100396290C (zh) 妇科外用抗菌泡沫剂
CN1379146A (zh) 复合型(Ag+Ag2O)防集聚纳米银抗菌非织造布及工业化生产工艺
US20150209386A1 (en) Copper Containing Materials for Treating Wounds, Burns and Other Skin Conditions
CN107281095A (zh) 一种妇科用抗菌养护凝胶
Khodke et al. Silver nanoparticles-A review
CN107583050A (zh) 一种用于治疗宫颈炎的药物组合物及用途
JP2022091508A (ja) 感染防止及び消臭洗浄剤、並びに、それを用いた衛生及び生活用品
TWI324060B (fr)
KR20180031513A (ko) 금 나노 입자가 도포된 기능성 기저귀, 생리대 및 그 제조방법
Aftab et al. Antiseptic Activity of Silver Nanoparticles Against E. Coli O157: H7
CN1257191C (zh) 改性天然高分子材料及其在卫生巾保健药物包覆中的应用
CN116058388A (zh) 一种可杀菌和抑制病毒的组合物及应用
CN115671280A (zh) 一种铜源异质结纳米抗菌剂及其制备方法和应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 018231578

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP